AbbVie Inc. ABBV

264.34 (0.78) (0.29%) as of 25 Sep
Market cap
$467.4B
P/E
74.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

AbbVie Inc. (ABBV) EV/Sales

As of 25 September 2026, AbbVie Inc. (ABBV) trades at a EV/Sales of 8.3×. Over the past ten years it has ranged from 3.7× (March 2020) to 8.3× (October 2025); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 7.6× 14.29%
FY2024 6.7× 10.13%
FY2023 6.1× 2.97%
FY2022 5.9× 7.89%
FY2021 5.5× (2.49%)
FY2020 5.6× 17.82%
FY2019 4.7× (10.80%)
FY2018 5.3× (18.67%)
FY2017 6.5× 27.44%
FY2016 5.1× (1.80%)

Quarterly

Period EV/Sales Change
Jun 2026 7.9× 10.83%
Mar 2026 7.1× (6.41%)
Dec 2025 7.6× (3.76%)
Sep 2025 7.9× 17.86%
42 more quarters

Against its own ten years

Low 3.7× High 8.3×
Ten-year median 5.6×
Current reading's percentile 100

EV/Sales against peers

Company EV/Sales
PFE Pfizer Inc. compare 3.4×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.6×
MRK Merck & Co., Inc. compare 6.2×
JNJ Johnson & Johnson compare 6.8×
GILD Gilead Sciences, Inc. compare 6.9×
AMGN Amgen Inc. compare 7.0×
ABBV AbbVie Inc. 8.3×
LLY Eli Lilly and Company compare 13.8×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ABBV